{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:51:02Z","timestamp":1785901862714,"version":"3.56.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.xcrm.2026.102799","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T13:52:54Z","timestamp":1778766774000},"page":"102799","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Trial-ready external controls for gene therapy: The MATCH cohort in maple syrup urine disease"],"prefix":"10.1016","volume":"7","author":[{"given":"Karlla W.","family":"Brigatti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashlin","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Sweigert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joelle","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alanna","family":"Koehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace Loudon","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura E.","family":"Poskitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent J.","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6429-8657","authenticated-orcid":false,"given":"Kevin A.","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.102799_bib1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ymgme.2020.01.006","article-title":"Branched-chain alpha-ketoacid dehydrogenase deficiency (maple syrup urine disease): Treatment, biomarkers, and outcomes","volume":"129","author":"Strauss","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.xcrm.2026.102799_bib2","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"1971","article-title":"Maple syrup urine disease (branched-chain ketoaciduria)","author":"Chuang","year":"2001"},{"key":"10.1016\/j.xcrm.2026.102799_bib3","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/ajcn\/68.1.72","article-title":"A molecular model of human branched-chain amino acid metabolism","volume":"68","author":"Suryawan","year":"1998","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.xcrm.2026.102799_bib4","series-title":"Pediatric Critical Care: Text and Study Guide","first-page":"1351","article-title":"Metabolic Crises","author":"Strauss","year":"2021"},{"key":"10.1016\/j.xcrm.2026.102799_bib5","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0022-3476(05)81036-4","article-title":"Cerebral edema causing death in children with maple syrup urine disease","volume":"119","author":"Riviello","year":"1991","journal-title":"J. Pediatr."},{"key":"10.1016\/j.xcrm.2026.102799_bib6","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1007\/s10897-012-9490-1","article-title":"Young adults with MSUD and their transition to adulthood: psychosocial issues","volume":"21","author":"Packman","year":"2012","journal-title":"J. Genet. Couns."},{"key":"10.1016\/j.xcrm.2026.102799_bib7","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s10897-007-9114-3","article-title":"Psychosocial issues in families affected by maple syrup urine disease","volume":"16","author":"Packman","year":"2007","journal-title":"J. Genet. Couns."},{"key":"10.1016\/j.xcrm.2026.102799_bib8","article-title":"Caregiver burden, and parents' perception of disease severity determine health-related quality of life in paediatric patients with intoxication-type inborn errors of metabolism","volume":"31","author":"B\u00f6sch","year":"2022","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.xcrm.2026.102799_bib9","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/jimd.12301","article-title":"Health-related quality of life in paediatric patients with intoxication-type inborn errors of metabolism: Analysis of an international data set","volume":"44","author":"B\u00f6sch","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.xcrm.2026.102799_bib10","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/1477-7525-11-158","article-title":"Assessment of quality of life of the children and parents affected by inborn errors of metabolism with restricted diet: preliminary results of a cross-sectional study","volume":"11","author":"Fabre","year":"2013","journal-title":"Health Qual. Life Outcomes"},{"key":"10.1016\/j.xcrm.2026.102799_bib11","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/jimd.12648","article-title":"The impact of liver transplantation on health-related quality of life in (acute) intoxication-type inborn errors of metabolism","volume":"46","author":"Greco","year":"2023","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.xcrm.2026.102799_bib12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jpeds.2022.08.060","article-title":"Individual and Family Determinants for Quality of Life in Parents of Children with Inborn Errors of Metabolism Requiring a Restricted Diet: A Multilevel Analysis Approach","volume":"254","author":"Ouattara","year":"2023","journal-title":"J. Pediatr."},{"key":"10.1016\/j.xcrm.2026.102799_bib13","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jpeds.2021.11.021","article-title":"Determinants of Quality of Life in Children with Inborn Errors of Metabolism Receiving a Restricted Diet","volume":"242","author":"Ouattara","year":"2022","journal-title":"J. Pediatr."},{"key":"10.1016\/j.xcrm.2026.102799_bib14","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1600-6143.2005.01209.x","article-title":"Elective liver transplantation for the treatment of classical maple syrup urine disease","volume":"6","author":"Strauss","year":"2006","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.xcrm.2026.102799_bib15","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jpeds.2011.06.033","article-title":"Liver transplantation for classical maple syrup urine disease: long-term follow-up in 37 patients and comparative United Network for Organ Sharing experience","volume":"160","author":"Mazariegos","year":"2012","journal-title":"J. Pediatr."},{"key":"10.1016\/j.xcrm.2026.102799_bib16","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1136\/archdischild-2015-310023","article-title":"Liver transplantation in children: state of the art and future perspectives","volume":"103","author":"Kohli","year":"2018","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.xcrm.2026.102799_bib17","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1046\/j.1471-4159.1996.66010378.x","article-title":"Astrocyte leucine metabolism: significance of branched-chain amino acid transamination","volume":"66","author":"Yudkoff","year":"1996","journal-title":"J. Neurochem."},{"key":"10.1016\/j.xcrm.2026.102799_bib18","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1046\/j.1471-4159.1998.70031304.x","article-title":"Rate of glutamate synthesis from leucine in rat brain measured in vivo by 15N NMR","volume":"70","author":"Kanamori","year":"1998","journal-title":"J. Neurochem."},{"key":"10.1016\/j.xcrm.2026.102799_bib19","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1002\/jnr.21444","article-title":"The glutamate-glutamine cycle is not stoichiometric: fates of glutamate in brain","volume":"85","author":"McKenna","year":"2007","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.xcrm.2026.102799_bib20","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1046\/j.1471-4159.1998.71020863.x","article-title":"Role of branched-chain aminotransferase isoenzymes and gabapentin in neurotransmitter metabolism","volume":"71","author":"Hutson","year":"1998","journal-title":"J. Neurochem."},{"key":"10.1016\/j.xcrm.2026.102799_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/jimd.70003","article-title":"Contribution of Brain Intrinsic Branched-Chain Amino Acid Metabolism in a Novel Mouse Model of Maple Syrup Urine Disease","volume":"48","author":"Kuhs","year":"2025","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.xcrm.2026.102799_bib22","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1172\/JCI67217","article-title":"Biochemical correlates of neuropsychiatric illness in maple syrup urine disease","volume":"123","author":"Muelly","year":"2013","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2026.102799_bib23","doi-asserted-by":"crossref","first-page":"1531S","DOI":"10.1093\/jn\/135.6.1531S","article-title":"Brain amino acid requirements and toxicity: the example of leucine","volume":"135","author":"Yudkoff","year":"2005","journal-title":"J. Nutr."},{"key":"10.1016\/j.xcrm.2026.102799_bib24","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1046\/j.1471-4159.1994.63041508.x","article-title":"Inhibition of astrocyte glutamine production by alpha-ketoisocaproic acid","volume":"63","author":"Yudkoff","year":"1994","journal-title":"J. Neurochem."},{"key":"10.1016\/j.xcrm.2026.102799_bib25","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/jimd.12604","article-title":"Successful treatment of severe MSUD in Bckdhb(-\/-) mice with neonatal AAV gene therapy","volume":"47","author":"Pontoizeau","year":"2024","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.xcrm.2026.102799_bib26","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1038\/s41467-022-30880-w","article-title":"Neonatal gene therapy achieves sustained disease rescue of maple syrup urine disease in mice","volume":"13","author":"Pontoizeau","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102799_bib27","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ymgme.2021.08.003","article-title":"Muscle-directed AAV gene therapy rescues the maple syrup urine disease phenotype in a mouse model","volume":"134","author":"Greig","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.xcrm.2026.102799_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ads0539","article-title":"BCKDHA-BCKDHB digenic gene therapy restores metabolic homeostasis in two mouse models and a calf with classic maple syrup urine disease","volume":"17","author":"Wang","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.102799_bib29","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.cct.2013.09.003","article-title":"The ethics of placebo-controlled trials: methodological justifications","volume":"36","author":"Millum","year":"2013","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.xcrm.2026.102799_bib30","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1089\/hum.2010.230","article-title":"When ethics constrains clinical research: trial design of control arms in \u201cgreater than minimal risk\u201d pediatric trials","volume":"22","author":"de Melo-Martin","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.xcrm.2026.102799_bib31","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1186\/s13023-022-02529-w","article-title":"Sharing is caring: a call for a new era of rare disease research and development","volume":"17","author":"Denton","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.xcrm.2026.102799_bib32","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13023-021-01806-4","article-title":"Data silos are undermining drug development and failing rare disease patients","volume":"16","author":"Denton","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.xcrm.2026.102799_bib33","doi-asserted-by":"crossref","first-page":"398","DOI":"10.4997\/jrcpe.2020.409","article-title":"Retrospective studies - utility and caveats","volume":"50","author":"Talari","year":"2020","journal-title":"J. R. Coll. Physicians Edinb."},{"key":"10.1016\/j.xcrm.2026.102799_bib34","unstructured":"FDA (2023). Draft Guidance: Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products. https:\/\/www.fda.gov\/drugs\/guidance-compliance-regulatory-information\/guidances-drugs."},{"key":"10.1016\/j.xcrm.2026.102799_bib35","article-title":"The estimands framework: a primer on the ICH E9(R1) addendum","volume":"384","author":"Kahan","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.xcrm.2026.102799_bib36","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1056\/NEJMp2513633","article-title":"Statistics in Medicine - What's in an Estimand?","volume":"394","author":"Troxel","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102799_bib37","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1542\/peds.14.5.462","article-title":"A new syndrome: progressive familial infantile cerebral dysfunction associated with an unusual urinary substance","volume":"14","author":"Menkes","year":"1954","journal-title":"Pediatrics"},{"key":"10.1016\/j.xcrm.2026.102799_bib38","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1186\/s13023-025-04043-1","article-title":"Cerebral edema in maple syrup urine disease: spectrum of clinical presentation and treatment outcomes","volume":"20","author":"Sulaiman","year":"2025","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.xcrm.2026.102799_bib39","unstructured":"Strauss, K.A., Puffenberger, E.G., and Morton, D.H. (2009). Maple Syrup Urine Disease. http:\/\/www.ncbi.nlm.nih.gov\/bookshelf\/br.fcgi?book=gene&part=msud."},{"key":"10.1016\/j.xcrm.2026.102799_bib40","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1373\/clinchem.2007.098434","article-title":"Second-tier test for quantification of alloisoleucine and branched-chain amino acids in dried blood spots to improve newborn screening for maple syrup urine disease (MSUD)","volume":"54","author":"Oglesbee","year":"2008","journal-title":"Clin. Chem."},{"key":"10.1016\/j.xcrm.2026.102799_bib41","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1093\/clinchem\/45.10.1734","article-title":"Significance of L-alloisoleucine in plasma for diagnosis of maple syrup urine disease","volume":"45","author":"Schadewaldt","year":"1999","journal-title":"Clin. Chem."},{"key":"10.1016\/j.xcrm.2026.102799_bib42","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1203\/00006450-199111000-00007","article-title":"Oral L-alloisoleucine loading studies in healthy subjects and in patients with maple syrup urine disease","volume":"30","author":"Schadewaldt","year":"1991","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.xcrm.2026.102799_bib43","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1096-7192(03)00144-6","article-title":"Relationship of causative genetic mutations in maple syrup urine disease with their clinical expression","volume":"80","author":"Nellis","year":"2003","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.xcrm.2026.102799_bib44","first-page":"86","article-title":"WHO Motor Development Study: windows of achievement for six gross motor development milestones","volume":"450","year":"2006","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.xcrm.2026.102799_bib45","unstructured":"FDA (2019). Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products. https:\/\/www.regulations.gov."},{"key":"10.1016\/j.xcrm.2026.102799_bib46","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.2105\/AJPH.2011.300569","article-title":"One community's effort to control genetic disease","volume":"102","author":"Strauss","year":"2012","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.xcrm.2026.102799_bib47","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1590\/1414-431X20143830","article-title":"Successful domino liver transplantation in maple syrup urine disease using a related living donor","volume":"47","author":"Feier","year":"2014","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.xcrm.2026.102799_bib48","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1007\/s12035-017-0831-9","article-title":"Time Is Motor Neuron: Therapeutic Window and Its Correlation with Pathogenetic Mechanisms in Spinal Muscular Atrophy","volume":"55","author":"Govoni","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.xcrm.2026.102799_bib49","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s40264-021-01107-6","article-title":"Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy","volume":"44","author":"Day","year":"2021","journal-title":"Drug Saf."},{"key":"10.1016\/j.xcrm.2026.102799_bib50","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","article-title":"Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102799_bib51","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1186\/s13287-025-04630-w","article-title":"Adenine base editing rescues disrupted BCKDH function and reduces BCAAs toxic accumulation in maple syrup urine disease patient iPSC-hepatic organoids","volume":"16","author":"Zhang","year":"2025","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.xcrm.2026.102799_bib52","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1542\/peds.109.6.999","article-title":"Diagnosis and treatment of maple syrup disease: a study of 36 patients","volume":"109","author":"Morton","year":"2002","journal-title":"Pediatrics"},{"key":"10.1016\/j.xcrm.2026.102799_bib53","doi-asserted-by":"crossref","first-page":"17792","DOI":"10.1074\/jbc.M313879200","article-title":"Structural and biochemical basis for novel mutations in homozygous Israeli maple syrup urine disease patients: a proposed mechanism for the thiamin-responsive phenotype","volume":"279","author":"Chuang","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.xcrm.2026.102799_bib54","doi-asserted-by":"crossref","first-page":"13110","DOI":"10.1074\/jbc.273.21.13110","article-title":"Impaired assembly of E1 decarboxylase of the branched-chain alpha-ketoacid dehydrogenase complex in type IA maple syrup urine disease","volume":"273","author":"Wynn","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.xcrm.2026.102799_bib55","unstructured":"FDA (2026). Biomarker Qualification Program. https:\/\/www.fda.gov\/drugs\/drug-development-tool-ddt-qualification-programs\/biomarker-qualification-program."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126002168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126002168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:19:51Z","timestamp":1785899991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126002168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2666379126002168"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102799","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trial-ready external controls for gene therapy: The MATCH cohort in maple syrup urine disease","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102799","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102799"}}